Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial-Reference-Cited by-同舟云学术

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial

Published:2014-05-01 Issue:7 Volume:73 Page:1331-1339
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

de Jong P H,Hazes J M,Han H K,Huisman M,van Zeben D,van der Lubbe P A,Gerards A H,van Schaeybroeck B,de Sonnaville P B,van Krugten M V,Luime J J,Weel A E

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference36 articles.

1. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update;Smolen;Ann Rheum Dis,2014

2. Rheumatoid arthritis;Scott;Lancet,2010

3. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative;Aletaha;Ann Rheum Dis,2010

4. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis;Singh;Arthritis Care Res (Hoboken),2012

5. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis;Arnett;Arthritis Rheum,1988

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial;RMD Open;2024-08

2. The prognostic value of IgA anti-citrullinated protein antibodies and rheumatoid factor in an early arthritis population with a treat-to-target approach;Immunologic Research;2024-07-03

3. 2023 Management Recommendations of Bangladesh Rheumatology Society on Pharmacological Treatment of Rheumatoid Arthritis With Synthetic and Biologic Disease-Modifying Drugs;Cureus;2024-04-30

4. Responsiveness and sensitivity of PROMs to change in disease activity status in early and established rheumatoid arthritis;Rheumatology;2024-04-04

5. Clinical practice guidelines for the early detection, diagnosis, treatment, and follow-up of patients with rheumatoid arthritis. Colombian Association of Rheumatology, 2022;Revista Colombiana de Reumatología (English Edition);2024-04